



**PRESS RELEASE  
FOR IMMEDIATE RELEASE**

---

**Medicago completes cGMP qualification of its manufacturing facility**

**Quebec City, Quebec, April 16, 2008** — Medicago Inc. (TSX-V: MDG) today announced that it has successfully completed the current Good Manufacturing Practices ("cGMP") qualification of its manufacturing facility located in the Technology Park of Québec City, Canada. cGMP rules and regulations governing the development, manufacturing and control of pharmaceutical products apply to all stages of production, from early development to marketed products. This qualification will allow Medicago to produce clinical grade materials of H5N1 Avian Influenza Virus-Like Particles ("VLP") vaccine candidates and other influenza vaccines.

"The qualification of our facility and quality control procedures to meet the cGMP and ISO standards are another important milestone in our program to advance our VLP pandemic influenza vaccine candidates," said Andy Sheldon, President and CEO of Medicago. "We are now in a position to take full advantage of our manufacturing capability and initiate the production of VLP vaccines this year to support our human clinical trials."

"cGMP qualification is always a great challenge for all companies and we are especially proud that Medicago has attained this level of excellence," said Louis Vézina, Chief Scientific Officer. "Now that we have achieved this milestone, we have strengthened our competitive position for all our products."

Medicago's facility is made up of 11,000 sq. ft. of Biosafety Level 2 greenhouse spaces for plant growth, as well as 3,000 sq. ft. of cGMP manufacturing suites for plant manipulation, product recovery and purification.

**About Medicago Inc.**

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market.

Additional information about Medicago is available at [www.medicago.com](http://www.medicago.com).

**Forward-Looking Statements**

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

- 30 -

*The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release*

**Contact Information**

**Medicago Inc.**  
Andy Sheldon  
President and CEO  
(418) 658-9393

**The Equicom Group Inc.**  
Arianna Vanin  
Investor Relations  
(514) 844-4680  
[avanin@equicomgroup.com](mailto:avanin@equicomgroup.com)